scaldex - maść
barbara maria owoc wspólnik spółki cywilnej owoc ointment dorian jacek owoc wspólnik spółki cywilnej owoc ointment - calendulae tinctura + wyciąg z propolisu 20% + bacytracyna + witamina a - maść - -
dentinox n 15% + 0,34% + 0,32% Żel do stosowania na dziąsła
dentinox gesellschaft fuer pharmazeutische praeparate lenk & schuppan kg - chamomillae tinctura + lidocaini hydrochloridum + macrogoli aether laurilicus - Żel do stosowania na dziąsła - 15% + 0,34% + 0,32%
sirupus pini compositus (420 mg + 64 mg + 3,2 mg)/5 ml syrop
wrocławskie zakłady zielarskie "herbapol" s.a. - pini extractum + foeniculi tinctura + codeini phosphas - syrop - (420 mg + 64 mg + 3,2 mg)/5 ml
stomatosol (304 mg + 304 mg + 304 mg)/ml płyn do stosowania w jamie ustnej
elanda zakład produkcji Środków farmaceutycznych sp.j. b.kazub, a.orłowski - arnicae tinctura; tormentillae tinctura; gallae tinctura - płyn do stosowania w jamie ustnej - (304 mg + 304 mg + 304 mg)/ml
syrop sosnowy złożony aflofarm (427,7 mg + 64,8 mg + 3,24 mg)/5 ml syrop
aflofarm farmacja polska sp. z o.o. - pini extractum + anisi tinctura + codeini phosphas - syrop - (427,7 mg + 64,8 mg + 3,24 mg)/5 ml
antinervinum (1032 mg + 903 mg + 645 mg)/5 ml syrop
boni fratres pharmaceutical sp. z o.o. - valerianae tinctura + crataegi tinctura + lupuli strobili tinctura - syrop - (1032 mg + 903 mg + 645 mg)/5 ml
neo-tormentil (20 g + 2 g + 1 g + 8 g)/100 g maść
laboratorium galenowe olsztyn sp. z o.o. - zinci oxidum + ammonii bituminosulfonas + borax + tormentillae tinctura - maść - (20 g + 2 g + 1 g + 8 g)/100 g
krople żołądkowe amara - krople doustne, roztwór
zakład farmaceutyczny "amara" sp. z o.o. - hyperici intractum + menthae piperitae tinctura + valerianae tinctura + amara tinctura - krople doustne, roztwór - -
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. zobacz rozdziały 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - Środki przeciwnowotworowe - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.